Eli Lilly's Foundayo (orforglipron) 17.2 mg showed significantly greater weight loss (1.5% more) and A1C reduction (0.3% more) than oral semaglutide 25 mg after 52 weeks in adults with type 2 diabetes, based on an indirect comparison of ACHIEVE-3 and PIONEER PLUS trial data. These results, presented at the EASD meeting, suggest Foundayo could be a more effective oral treatment option with simpler administration. Foundayo is FDA-approved for obesity and is being studied for multiple conditions including type 2 diabetes. Further head-to-head trials may confirm these findings and influence treatment choices.
Eli Lilly And Co (LLY) shares trade at USD 1,188.54 on Pluang as of Sep 29, 2026 14:11 WIB, up 0.22% for the day. The stock holds a market cap of $1.05 trillion with a dividend yield of 0.58%. Pluang investors typically hold LLY for 93 days, with current order activity showing 78% selling and 22% buying interest.
Eli Lilly launched the 'Change the Course Commitment' aiming to treat as many diabetes and obesity patients in low- and middle-income countries (LMICs) as in high-income countries by 2040. Currently, only one in four patients in LMICs have access to ...
The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, marking a useful extension to its diabetes treatments. While the stock rose 2.85% to $1,183.76, this new insulin is unlikely to significantly change the...
The FDA has approved Olumiant (baricitinib), a once-daily pill, for treating severe alopecia areata (AA) in pediatric patients aged 12 and older. This approval is based on positive results from the BRAVE-AA-PEDS Phase 3 study, showing significant sca...
Novo Nordisk revealed a strategy to boost growth beyond its top obesity drugs Wegovy and Ozempic, facing patent expirations in the early 2030s. Despite promising a pipeline of new drugs, investors remain skeptical as Eli Lilly gains market share, esp...
The US FDA has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, offering a new alternative to daily insulin injections. Onswik, used alongside diet and exercise, can reduce injection frequency by over 300 times...
